Ethical issues in funding orphan drug research and development

Journal of Medical Ethics

Volumn 31, Issue 3, 2005, Pages 164-168

  Gericke, Christian A ^a   Riesberg, A ^a   Busse, R ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARTICLE; BENEFICENCE; CONFLICT; DRUG LEGISLATION; DRUG RESEARCH; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN RIGHTS; JUSTICE; MEDICAL ETHICS; MORALITY; PATIENT ABANDONMENT; RARE DISEASE; RESOURCE ALLOCATION; TROPICAL DISEASE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH;

DRUG EVALUATION; ETHICS, PHARMACY; HUMANS; MORALS; ORPHAN DRUG PRODUCTION; PHARMACOLOGY, CLINICAL; RESEARCH; RESEARCH SUPPORT;

EID: 15044363337     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2003.007138     Document Type: Article

References (40)

1. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects. www.cioms.ch/frame_guidelines_nov_2002.htm (accessed 21 October 2003).
2. Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development Geneva: World Health Organization, 2001.
3. Médecins Sans Frontières. Fatal Imbalance. The Crisis in Research and Development for Drugs for Neglected Diseases. Geneva: Médecins Sans Frontières Access to Essential Medicines Campaign and the Drugs for Neglected Diseases Working Group, 2001.
4. Global Forum on Health Research. Monitoring financial flows for health research. Geneva: Global Forum for Health Research, 2001.
5. National Library of Medicine. Medical Subject Headings. Bethesda: National Library of Medicine, 1991.
6. Orphanet. What is an orphan drug? www.orpha.net/consor/cgi-bin/home_Info.php?PHPSESSID= c2c2ccf314be9c80bf3b40a695dabb36&file=MoDf (accessed 15 September 2003).
7. Pabst JY. Médicaments orphelins: quelques aspects juridiques, éthiques et économiques. Rev Epidemiol Sante Publique 2001;49:387-96.
8. European Parliament and the Council of the European Union Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000;L18:1-5.
9. European Parliament and the Council of the European Union Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts " similar medicinal product" and "clinical superiority". Official Journal of the European Communities 2000;L103:5-8.
10. European Commission. Communication from the Commission on Regulation [EC] No 141/2000 on orphan medicinal products. Official Journal of the European Union 2003;C178:2.
11. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. Oxford: Oxford University Press, 2001.
12. Gillon R. Medical ethics: four principles plus attention to scope. BMJ 1994;309:184-8.
13. Beauchamp TL, Childress JF. Justice. Principles of Biomedical Ethics. Oxford: Oxford University Press, 2001:225-82.
14. Sassi F, Archard L, Le Grand J. Equity and the economic evaluation of healthcare. Health Technol Assess 2001; 5:1-138.
15. Beauchamp TL, Childress JF. Moral theories. Principles of Biomedical Ethics. Oxford: Oxford University Press, 2001:337-83.
16. Cookson R, Dolan P. Principles of justice in health care rationing. J Med Ethics 2000;26:323-9.
17. DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ 2001; 10: 107-42.
18. Global Alliance for TB Drug Development. The Economics of TB Drug Development. New York: Global Alliance for TB Drug Development, 2001.
19. Global Forum for Health Research. The 10/90 Report on Health Research 2001-2002. Geneva: Global Forum for Health Research, 2002.
20. Gericke CA, Kurowski C, Ranson MK, et al. Feasibility of Scaling-up Interventions: The Role of Intervention Design Working Paper No. 13, Disease Control Priorities Project. Bethesda, Fogarty International Center, National Institutes of Health, 2003, www.fic.nih.gov/dcpp/wps/wp13.pdf (accessed 15 December 2003).
21. Daniels N. Is there a right to health care and, if so, what does it encompass? In: Kuhse H, Singer P, eds. A Companion to Bioethics. Oxford: Blackwell, 1998:316-25.
22. Den Exter A, Hermans H. The right to health care: a changing concept? In: Den Exter A, Hermans H, eds. The Right to Health Care in Several European Countries. The Hague: Kluwer Law International, 1999:1-10.
23. Richards FO, Miri E, Meredith S, et al. Onchocerciasis. Bull World Health Organ 1998;76(suppl 2):147-9.
24. Beauchamp TL, Childress JF. Beneficence. Principles of Biomedical Ethics. Oxford: Oxford University Press, 2001:165-224.
25. Landman WA, Henley LD. Equitable rationing of highly specialised health care services for children: a perspective from South Africa. J Med Ethics 1999;25:224-9.
26. Issell LM, Kahn D. The economic value of caring. Health Care Manage Rev 1998;23:43-53.
27. Rhodes R. Organ transplantation. In: Kuhse H, Singer P, eds. A Companion to Bioethics. Oxford: Blackwell, 1998:329-42.
28. Royal College of Physicians. About the College. www.rcplondon.ac.uk/college/about_home.htm (accessed 26 August 2003).
29. Ad hoc Committee on Health Research. Investing in Health Research and Development. Geneva: World Health Organizatiion, 1996.
30. Willis R. The Works of William Harvey. London: Sydenham Society, 1847:616.
31. Maeder T. Adopting orphan diseases. www.redherring.com/insider/2001/0122/tech-mag-90-orphan012201.html (accessed 6 May 2003).
32. Goodman B. The biotech boom: big money in orphans. vvww.redherring.com/insider/2001/0727/A80019848.html (accessed 6 May 2003).
33. Zelzer E, Olsen BR. The genetic basis for skeletal diseases. Nature 2003;423:343-8.
34. Federal Drug Agency. List of All Orphan Products Designations and Approvals. www.fda.gov/orphan/designat/alldes.rtf (accessed 2 September 2003).
35. European Agency for the Evaluation of Medicinal Products (EMEA). Press Release. 35th Meeting of the Committee for Orphan Medicinal Products. www.emea.eu.int/pdfs/human/comp/117303en.pdf (accessed 2 September 2003).
36. Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation and the legitimacy problem for insurers. Philos Public Affairs 1997;26:303-50.
37. Benatar SR, Singer PA. A new look at international research ethics. BMJ 2000;321:824-6.
38. Gericke C. Directory of poverty and health research Report for the Department of Health and Development. Geneva: World Health Organization, 2001, www.iphn.org/DirectorywebFINAL.doc (accessed 29 October 2003).
39. Global Forum on Health Research. Strategic Orientations 2003-2005. www.globalforumhealth.org (accessed 22 October 2003).
40. The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund reports its first country results. Geneva: The Global fund to fight AIDS, Tuberculosis and Malasia, July 2004. www.theglobalfund.org/en/media_center/press/pr_040711b.asp (accessed 15 September 2004).